Federal Circuit Affirms PTAB Ruling, Upholding Ravgen’s Patent in $372M Legal Battle with Streck

The United States Court of Appeals for the Federal Circuit has upheld a decision by the Patent Trial and Appeal Board (PTAB) that rejected biotechnology company Streck’s attempt to challenge several claims in a patent held by Ravgen Inc. This patent is central to a $372 million judgment that Ravgen secured in a previous legal battle against Labcorp. For legal professionals interested in the specifics of this case, further details are available through Law360’s coverage.